Aptevo Therapeutics (APVO)
(Real Time Quote from BATS)
$4.12 USD
+0.06 (1.48%)
Updated Mar 28, 2024 10:42 AM ET
2-Buy of 5 2
D Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Aptevo Therapeutics Inc. [APVO]
Reports for Purchase
Showing records 1 - 20 ( 92 total )
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology and Medical Device Conference Note
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - 36th Annual Roth Conference, Biotechnology Track, March 17-19
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
3Q23: APVO436 Phase 2 On Deck, ALG.APV527 In Phase 1, Funded Into 4Q24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Healthcare: HC Opportunities Conference in NYC on October 12th
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Healthcare: HC Opportunities Conference in NYC on October 12th
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
2Q23: APVO436 Phase 2 To Start, ALG.APV527 Data by YE23, Funded Into 3Q24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
New Positive Phase 1b APVO436 Data - DoR, Response Rate, Transplant Rate
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
1Q23: Clinical Pipeline Progressing, Funded Into Early 2024
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
4Q22: Clinical Pipeline Progressing, Funded Into Early 2024
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
First Patient Dosed in ALG.APV-527 Phase 1 Trial in 5T4+ Solid Tumors
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
APVO436 Outperforms In Venetoclax Naive AML, Phase 2 Should Start In 2H23
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
3Q22: APVO436 Progressing, New Clinical Trials to Start, Cash to Mid-2023
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Publication Demonstrates Promise of ALG.APV-527
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J